Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

Abstract Background Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiation the...

Full description

Bibliographic Details
Main Authors: Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yosuke Kasai, Akitada Yogo, Michio Yoshimura, Takashi Mizowaki, Norimitsu Uza, Akihisa Fukuda, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Yoshiya Kawaguchi, Shinji Uemoto, Etsuro Hatano
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
chemoradiotherapy
IMRT
intensity‐modulated radiotherapy
neoadjuvant therapy
pancreatic cancer
surgery
Online Access:https://doi.org/10.1002/cam4.6470

Similar Items

Similar Items